Everence Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Everence Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-7,091	Closed	-$1.3M	–	781
2021 Q2	$1.3M	Hold	7,091	–	–	0.11%	165
2021 Q1	$1.08M	Hold	7,091	–	–	0.1%	174
2020 Q4	$1.11M	Sell	7,091 -130	-2%	-$16.7K	0.11%	156
2020 Q3	$826K	Hold	7,221	–	–	0.09%	179
2020 Q2	$866K	Hold	7,221	–	–	0.1%	169
2020 Q1	$648K	Hold	7,221	–	–	0.09%	185
2019 Q4	$781K	Sell	7,221 -1,072	-13%	-$115K	0.12%	191
2019 Q3	$812K	Hold	8,293	–	–	0.13%	164
2019 Q2	$1.09M	Buy	8,293 +2,130	+35%	+$275K	0.18%	123
2019 Q1	$833K	Buy	6,163 +1,868	+43%	+$232K	0.15%	149
2018 Q4	$418K	Hold	4,295	–	–	0.1%	230
2018 Q3	$597K	Hold	4,295	–	–	0.12%	199
2018 Q2	$533K	Hold	4,295	–	–	0.11%	213
2018 Q1	$479K	Sell	4,295 -2,540	-37%	-$304K	0.11%	223
2017 Q4	$817K	Buy	6,835 +2,410	+54%	+$293K	0.18%	141
2017 Q3	$621K	Hold	4,425	–	–	0.14%	191
2017 Q2	$538K	Hold	4,425	–	–	0.13%	210
2017 Q1	$536K	Hold	4,425	–	–	0.14%	191
2016 Q4	$541K	Hold	4,425	–	–	0.16%	179
2016 Q3	$542K	Hold	4,425	–	–	0.16%	179
2016 Q2	$517K	Hold	4,425	–	–	0.16%	191
2016 Q1	$616K	Hold	4,425	–	–	0.19%	154
2015 Q4	$844K	Hold	4,425	–	–	0.27%	107
2015 Q3	$692K	Hold	4,425	–	–	0.24%	124
2015 Q2	$800K	Hold	4,425	–	–	0.26%	121
2015 Q1	$798K	Hold	4,425	–	–	0.27%	119
2014 Q4	$819K	Hold	4,425	–	–	0.28%	110
2014 Q3	$749K	Hold	4,425	–	–	0.27%	123
2014 Q2	$691K	Hold	4,425	–	–	0.26%	131
2014 Q1	$673K	Hold	4,425	–	–	0.27%	124
2013 Q4	$588K	Hold	4,425	–	–	0.24%	138
2013 Q3	$514K	Hold	4,425	–	–	0.22%	137
2013 Q2	$408K	Buy	+4,425	New	+$426K	0.18%	155

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Everence Capital Management's ALXN Position: Q3 2021 in Review

Everence Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 7,091 shares — an estimated $1.3M sold.

Everence Capital Management first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $1.3M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Everence Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Everence Capital Management sold 7,091 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.3M.
Everence Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
Everence Capital Management's Alexion Pharmaceuticals position peaked at $1.3M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Everence Capital Management's 13F filing for Q3 2021, filed 21 Oct 2021.